Cambridge Massachussets small cap biotech company called EDITAS. Drug : AGN-151587 FDA fast track ref EDIT-101 : cure genetic blindness LCA10 using Crispr Genome editing tech
November 28, 2020 at 14:45 PM EST
Hi. I listened to one of the very long-winded teaser videos regarding a revolutionary drug post Phase 1 of clinical trial with success in curing Genetic LCA10 using an in-vivo drug injected into the eye. The biotech company got to the point in FDA approval of being granted fast tracking and had to mandatorily report […]
